Key Highlights:
- In 2022, the prevalent cases of PV were highest in the US among the 7MM, which accounted for approximately 179,000 in 2022 and are expected to increase by 2032
- According to the publisher estimates, there were around 124,000 cases of asymptomatic and 185,000 cases of symptomatic PV in the 7MM in 2022. The prevalence is projected to increase during the forecasted period
- In the United States, there were approximately 69,000 males and about 38,000 females affected with PV in 2022. These cases are likely to increase by 2032.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
PV Disease Understanding
PV Overview
Polycythemia Vera is a rare blood disease in which the body makes excessive red blood cells. The extra red blood cells make the blood thicker than normal PV is the most common myeloproliferative neoplasm (MPN), the ultimate phenotype of the JAK2V1617F mutation. PV shares in common with its companion MPN, essential thrombocytosis (ET), and primary myelofibrosis (PMF), origin in a hematopoietic stem cell (HSC), constitutive activation of hematopoiesis with overproduction of morphologically normal blood cells, a tendency to extramedullary hematopoiesis, and transformation to bone marrow failure with myelofibrosis or acute leukemia, although at varying frequencies in each MPN, and JAK2 kinase mutation is behind the shared phenotypic features of all the above mentioned MPN's.PV usually occurs at an elderly age, and patients are at a higher risk than the usual percentage, as they are more prone to the risks and other comorbidities. Possible risk factors of PV include blood clots, splenomegaly, problems due to high levels of red blood cells, other blood disorders, etc.
Many individuals with PV receive treatment with certain drugs (myelosuppressive drugs) that suppress the formation of blood cells by the marrow. A chemotherapy drug known as hydroxyurea is most often used, along with another chemotherapy drug known as busulfan. Other drugs, such as chlorambucil and radioactive phosphorous, have been used. Still, these drugs, especially in individuals requiring long-term therapy, have been associated with an increased risk of leukemia. Ruxolitinib and ropeginterferon alfa-2B are the two FDA-approved drugs for the treatment of PV.
PV Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of PV, prevalent population of PV based on symptoms, gender-specific cases of PV, prevalence of PV by gene mutation, prevalence of PV based on risk, and age-specific prevalence of PV, in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain) the United Kingdom, and Japan from 2019 to 2032.Key Findings
This section provides a glimpse of the PV epidemiology in the 7MMCountry Wise-PV Epidemiology
- The epidemiology segment also provides the PV epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan
- The total prevalent cases of PV in the 7MM comprised of approximately 309,000 cases in 2022 and are projected to increase during the forecasted period
- The total diagnosed prevalent cases of PV in the United States were around 179,000 cases in 2022
- The United States contributed to the largest prevalent population of PV, acquiring ~58% of the 7MM in 2022. Whereas, EU4 and the UK, and Japan accounted for around 32% and 10% of total population share, respectively, in 2022
- Among the EU4 countries, Germany accounted for the largest number of PV cases followed by France, whereas Spain accounted for the lowest cases in 2022
- According to the publisher estimates, there were around 72,000 cases of asymptomatic and 107,000cases of symptomatic PV in the United States in 2022. The prevalence is projected to increase during the forecasted period
- In Japan, the prevalent PV cases were around 13,000 in males and 7,000 in females in 2022
Scope of the Report
- The report covers the descriptive overview of PV, explaining its causes, signs and symptoms, pathogenesis, and diagnosis
- Comprehensive insight has been provided into the PV epidemiology and treatment
- The report provides insight about the historical and forecasted patient pool of PV in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- A detailed review of PV epidemiology forecast is included in the report, covering the 7MM drug outreach
- The report provides an edge while developing business strategies, by understanding epidemiological trends
Report Highlights
- In the coming years, PV market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, increase in prevalent population
- As per the analysis, the major types of PV mutation include JAK2V617F and JAK2 exon 12
- The report also encompasses other major segments, i.e., total prevalent cases of PV, prevalent population of PV based on symptoms, gender-specific cases of PV, prevalence of PV by gene mutation, prevalence of PV based on risk, and age-specific prevalence of PV
PV Report Insights
- Patient Population
- Eleven Years Forecast
- 7MM Coverage
- PV Epidemiology Segmentation
Key Questions Answered
- What is the disease risk, burden, and unmet needs of PV?
- What is the historical PV patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the UK, and Japan?
- What would be the forecasted patient pool of PV at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PV?
- Out of the above-mentioned countries, which country would have the highest prevalent population of PV during the study period (2019-2032)?
- At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the PV
- To understand the future market competition in the PV market and Insightful review of the unmet needs.
- Quantify patient populations in the global PV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the best opportunities for PV in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
- The PV epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.
Table of Contents
1. Key Insights2. Report Introduction
3. Executive Summary of Polycythemia Vera (PV)
4. Key Events
5. Epidemiology and Market Methodology
6. Polycythemia Vera Market Overview at a Glance
6.1. Market Share by Therapies (%) Distribution of PV in 2022
6.2. Market Share by Therapies (%) Distribution of PV in 2032
7. Disease Background and Overview
7.1. Introduction
7.2. Polycythemia Vera: A Type of MPN
7.3. Signs and Symptoms of Polycythemia Vera
7.4. Causes of Polycythemia Vera
7.5. Complications due to Polycythemia Vera
7.6. Clinical Aspects of Polycythemia Vera
7.7. Pathophysiology of Polycythemia Vera
7.7.1. JAK2 V617F in Polycythemia Vera
7.8. Diagnosis of Polycythemia Vera
7.8.1. Diagnostic Algorithm of PV
7.9. Diagnostic Guidelines
7.9.1. British Society for Hematology Guidelines for Polycythemia Vera (2018)
7.9.2. WHO Diagnostic Guidelines for Polycythemia Vera (2018)
7.10. Treatment of Polycythemia Vera
7.10.1. Treatment Algorithm
7.11. Treatment Guidelines
7.11.1. European Society for Medical Oncology Guidelines for Polycythemia Vera (2015)
7.11.2. British Society for Hematology Guidelines for Polycythemia Vera (2018)
7.11.3. National Comprehensive Cancer Network Clinical Practice Guidelines for Polycythemia Vera (2022)
8. Epidemiology and Patient Population of Polycythemia Vera (PV) in the 7MM
8.1. Key Findings
8.1.1. Assumptions and Rationale
8.1.1.1. United States
8.1.1.2. EU4 and the UK
8.1.1.3. Japan
8.1.2. Total Prevalent Population of PV in the 7MM
8.2. The United States
8.2.1. Total Prevalent Population of PV in the United States
8.2.2. Prevalent Population of PV Based on Symptoms in the United States
8.2.3. Gender-specific Prevalence of PV in the United States
8.2.4. Prevalence of PV by Gene Mutation in the United States
8.2.5. Prevalence of PV Based on Risk in the United States
8.2.6. Age-specific Prevalence of PV in the United States
8.3. EU4 and the UK
8.3.1. Total Prevalent Population of PV in EU4 and the UK
8.3.2. Prevalent Population of PV Based on Symptoms in EU4 and the UK
8.3.3. Gender-specific Prevalence of PV in EU4 and the UK
8.3.4. Prevalence of PV by Gene Mutation in EU4 and the UK
8.3.5. Prevalence of PV Based on Risk in EU4 and the UK
8.3.6. Age-specific Prevalence of PV in EU4 and the UK
8.4. Japan
8.4.1. Total Prevalent Population of PV in Japan
8.4.2. Prevalent Population of PV Based on Symptoms in Japan
8.4.3. Gender-specific Prevalence of PV in Japan
8.4.4. Prevalence of PV by Gene Mutation in Japan
8.4.5. Prevalence of PV Based on Risk in Japan
8.4.6. Age-specific Prevalence of PV in Japan
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. Publisher Capabilities
11. Disclaimer
12. About the Publisher
List of Tables
Table 1: Summary of PV Epidemiology (2019-2032)
Table 2: Total Prevalent Population of PV in the US (2019-2032)
Table 3: Prevalent Population of PV Based on Symptoms in the US (2019-2032)
Table 4: Gender-specific Prevalence of PV in the US (2019-2032)
Table 5: Prevalence of PV by Gene Mutation in the US (2019-2032)
Table 6: Prevalence of PV Based on Risk in the US (2019-2032)
Table 7: Age-specific Diagnosed Prevalence of PV in the US (2019-2032)
Table 8: Total Prevalent Population of PV in EU4 and the UK (2019-2032)
Table 9: Prevalent Population of PV Based on Symptoms in EU4 and the UK (2019-2032)
Table 10: Gender-specific Prevalence of PV in Germany (2019-2032)
Table 11: Prevalence of PV by Gene Mutation in EU4 and the UK (2019-2032)
Table 12: Prevalence of PV Based on Risk in EU4 and the UK (2019-2032)
Table 13: Age-specific Prevalence of PV in EU4 and the UK (2019-2032)
Table 14: Total Prevalent Population of PV in Japan (2019-2032)
Table 15: Prevalent Population of PV Based on Symptoms in Japan (2019-2032)
Table 16: Gender-specific Prevalence of PV in Japan (2019-2032)
Table 17: Prevalence of PV by Gene Mutation in Japan (2019-2032)
Table 18: Prevalence of PV Based on Risk in Japan (2019-2032)
Table 19: Age-specific Prevalence of PV in Japan (2019-2032)
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Types of Myeloproliferative Neoplasm (MPN)
Figure 3: Schematic representation of the Epo-mediated signaling pathway
Figure 4: JAK/STAT Pathway In MPN
Figure 5: Structure of Janus Kinases
Figure 6: Impact of JAK2 V617F Allele
Figure 7: Diagnostic Algorithm of PV
Figure 8: Available treatments for PV
Figure 9: Total Prevalent Population of PV in the 7MM (2019-2032)
Figure 10: Total Prevalent Population of PV in the US (2019-2032)
Figure 11: Prevalent Population of PV Based on Symptoms in the US (2019-2032)
Figure 12: Gender-specific Prevalence of PV in the US (2019-2032)
Figure 13: Prevalence of PV by Gene Mutation in the US (2019-2032)
Figure 14: Prevalence of PV Based on Risk in the US (2019-2032)
Figure 14: Prevalence of PV Based on Risk in the US (2019-2032)
Figure 15: Age-specific Prevalence of PV in the US (2019-2032)
Figure 16: Total Prevalent Population of PV in EU4 and the UK (2019-2032)
Figure 17: Prevalent Population of PV Based on Symptoms in EU4 and the UK (2019-2032)
Figure 18: Gender-specific Prevalence of Polycythemia Vera in EU and the UK (2019-2032)
Figure 19: Prevalence of PV by Gene Mutation in EU4 and the UK (2019-2032)
Figure 20: Prevalence of PV Based on Risk in EU4 and the UK (2019-2032)
Figure 21: Age-specific Prevalence of PV in EU4 and the UK (2019-2032)
Figure 22: Total Prevalent Population of PV in Japan (2019-2032)
Figure 23: Prevalent Population of PV Based on Symptoms in Japan (2019-2032)
Figure 24: Gender-specific Prevalence of PV in Japan (2019-2032)
Figure 25: Prevalence of PV by Gene Mutation in Japan (2019-2032)
Figure 26: Prevalence of PV Based on Risk in Japan (2019-2032)
Figure 27: Age-specific Prevalence of PV in Japan (2019-2032)
